Purpose: The purpose of this study was to compare the clinical outcomes of abdominal aortic graft infection (AGI) treated with removal of the graft vs. graft preservation. Methods: The electronic databases PubMed, Embase, and Cochrane Library for studies that reported on AGI were searched. Observational studies and case series of at least 10 cases that reporting on the prevalence, microbiology, and outcomes of AGI were included. Results: Our search identified 23 studies that met our inclusion criteria, reporting on a total of 873 patients who underwent open surgical repair (OSR) or endovascular aneurysm repair (EVAR). Of these patients, 833 received graft removal, and 40 received graft preservation. The prevalence of AGI was reported to be 1.0% (95% confidence interval [CI], 0.5%–1.8%) after OSR and 0.4% (95% CI, 0%–1.1%) after EVAR. The pooled estimates of 1-year, 2-year, and 5-year mortality were 28.7% (95% CI, 19.4%–38.8%), 36.6% (95% CI, 24.6%–49.5%), and 51.8% (95% CI, 38.4%–65.1%) in the graft removal group and 16.1% (95% CI, 4.1%–32.2%), 18.5% (95% CI, 5.7%–35.1%), and 50.0% (95% CI, 31.6%–68.4%) in the graft preservation group.The 30-day mortality rate’s risk ratio (RR) for graft removal vs. preservation was 0.98 (95% CI, 0.40–2.38), while the 1-year mortality rate’s RR was 3.44 (95% CI, 1.60–7.42). Conclusion The 30-day mortality rate of AGI treatment was found to be high, whether using graft removal or preservation.In selected patients, implementing antibiotics with graft preservation as an initial management may be helpful in reducing the mortality rate.

The ventriculoatrial(VA) intervals during supraventricular tachycardia(VAsvt) and during pacing with same cycle length as tachycardia(VApace) were analysed in 48 patients to evaluate the usefullness in determining the mechanism of paroxysmal supraventricular tachycardia(PSVT) and the sites of accessory pathways. The results are as follows : 1)In differenciation AV nodal reentry from AV reentry mechanism, VAsvt(25.6+/-21.5 vs 148.0+/-27.7msec, p<0.01), VApace-VAsvt(135.3+/-15.7 vs 55.0+/-33.5msec,p<0.01), and VAsvt/VApace(0.15+/-0.10 vs 0.75+/-0.14,p<0.05) were useful. Cutoff values were 95msec in VAsvt, 110msec in VApace-VAsvt and 0.5 in VAsvt/VApace. 2) There were no overlaps in VA intervals between the AV nodal reentry group and the AV reentry group with posteroseptal accessory pathway.3) In AV reentry tachycardia, VApace-VAsvt>50msec(sensitivity 81%,specificity 100%) and VAsvt/VAace<0.7(sensitivity 71%, specificity 100%) suggested the high probability of left free wall accessory pathway. In Conclusion, VAsvt, VApace-VAsvt and VAsvt/VApace are useful parameters in determining the mechanism of PSVT and the sites of accessory pathways.
Humans ; Sensitivity and Specificity ; Tachycardia

BACKGROUND: The atheroma in aorta has been emphasized as a potential source of cerebral embolism after the wide use of TEE. But in Korea there has been no report on the frequency of the aortic atheroma in patients with cerbral infarctions. METHODS: Using transesophageal echocardiography, we evaluated aortic atheroma in the thoracic aorta of 44 patients with cerbral infarctions. The aortic atheroma was defined as a raised lesion with an irregular surface of echo shadow. RESULTS: The aortic atheromas were detected in 7 patients(16%) out of 44 patients with cerebral infarction. However, it were detected in only 3 patients out of 71 patients without cerebral infarction. The size of the lesions reaged from 6mm to 16mm(mean 10+/-3.5) and mobility were seen in 2 patients. The lesions were distributed throughout the thoracic aorta. CONCLUSION: Aortic atheroma is a potential source of cerebral infarction. TEE is a useful procedure for the evaluation of the patients with an undetermined cause of cerebral infarction.
Aorta ; Aorta, Thoracic ; Cerebral Infarction* ; Echocardiography, Transesophageal ; Humans ; Infarction ; Intracranial Embolism ; Korea ; Plaque, Atherosclerotic*

BACKGROUND: Familial hypercholesterolemia(FH) is an autosomal dominant inharited disorder. Total cholesterl level of FH heterozygotes is two to fourfold higher than that of normal population. Substained hypercholesterolemia results in cholesterol deposition on various organs or tissues and Achilles tendon xanthoma due to cholesterol deposition is one of the specific clinical findings of FH. One of the lipid lowering drugs, 3-hydroxy-3-methylglutaryl coenzyme A(HMG Co-A) reductase inhibitor effectively lowers the blood cholesterol level in patients with FH, but whether the cholesterol deposition can be regressed by the lipid lowering drugs is rarely reported. This study attemted to determine whether the tendon xanthoma can be regressed by lipid lowering drugs commonly used in patients with FH. METHODS: We analyzed procepectively the serum lipid levels of patients with heterozygous FH before and after lipid lowering therapy with HMG Co-A reductase inhibitor alone(Lovastatin or Pravastatin) or in combination with bile acid sequestrating resin(Cholestyramine). The Achilles tendon thickness was measured radiographically by using soft tissue technique. RESULT: Total 18 patients with heterozygotes FH(M : F=8 :10, mean age; 51.7+/-9.0 years) were treated with the HMG Co-A reductase inhibitor alone or combined with bile acid sequestrating resin and followed for mean 31.9+/-11.9 months. During that period, serum total cholesterol and low density lipoprotein cholesterol significantly fell from 329+/-42 mg/dl to 230+/-29 mg/dl and from 246+/-56 mg/dl to 151+/-28 mg/dl, respectively(p<0.001). Serum high density lipoprotein level increased and maintained 15.3% higher than basal level(p<0.01). Achilles tendon thickness decreased significantly from 13.3+/-3.1 mm to 11.9+/-3.2 mm(p<0.001) with percent reduction of 9.8+/-10.5%(range; 3.1-36.4%). The amount of change of tendon thickness was significantly correlated only with percent reductionof LDL(p=0.029) and female sex(p0.020) on univariate analysis, but it was found to be significantly correlated only with percent reduction of LDL on multivariate analysis(r=0.514,p=0.029). CONCLUSION: Achilles tendon xanthoma can be regressed by effective lipid lowering therapy with HMG Co-A reductase inhibitor alone or with bile acid sequestrating resin in patients with heterozygous FH. the regression of tendon xanthoma is likely to be related to reduction of serum LDL.
Achilles Tendon* ; Bile* ; Cholesterol ; Cholesterol, LDL ; Female ; Heterozygote ; Humans ; Hypercholesterolemia ; Hyperlipoproteinemia Type II* ; Lipoproteins ; Oxidoreductases* ; Tendons ; Xanthomatosis*

PURPOSE: This study was conducted in order to evaluate the effect of a newly developed explanation handout in the emergency department (ED) between patient and guardian. METHODS: From August 24, 2013 to September 24, 2013, interviews were conducted to patient accompanying guardian, discharged from Seoul Medical Center ED. Four groups were divided according to non-handout or handout in addition to patient or guardian. Each group consisted of 50 candidates and allocated according to a random table. The explanation handout could be easily applicable automatically through the Electronic Medical Record. It contains the results of laboratory tests along with cautions by diagnosis. After discharge explanation, a survey was conducted in each group using questionnaires for evaluation of the effect on medical service satisfaction. RESULTS: A total of 97 candidates(49 patients, 48 guardians) in the non-handout group, and 99 candidates(50 patients, 49 guardians) in the handout group were enrolled. No statistical difference in epidemiology, except explanation time, was observed between the two groups. The handout group showed a higher score in all factors, however, explanation by physician (p<0.001), mean 3.61(+/-0.72) to 3.87(+/-0.73), understanding of medical status (p<0.001), mean 3.51(+/-0.75) to 4.11(+/-0.71), medical evaluation and treatment (p=0.001), mean 3.59(+/-0.72) to 3.92(+/-0.75), kindness of physician (p<0.001), mean 3.74(+/-0.81) to 4.09(+/-0.67), overall satisfaction (p<0.001), mean 3.60(+/-0.75) to 3.97(+/-0.75), willingness of revisit (p=0.023), mean 3.87(+/-0.73) to 4.09(+/-0.61), and willingness of recommendation (p<0.001), mean 3.66(+/-0.82) to 4.09(+/-0.66) showed statistically meaningful results. In a sub-analysis, statistically meaningful results were reanalyzed between patient and guardian. In the non-handout group, guardian showed higher scores in mean value in all factors, however, statistically meaningful results were observed for all factors, except understanding of medical status and medical evaluation and treatment. By application of the handout, 99 patients and 97 guardians showed higher scores in mean value in all factors. Patients showed statistically meaningful results in all factors but just in understanding of medical status in guardian. CONCLUSION: Results of this study showed that the explanation handout effectively increased medical service satisfaction. The effect of the explanation handout was more prominent in patients than guardians.
Diagnosis ; Electronic Health Records ; Emergencies* ; Emergency Medical Services ; Emergency Service, Hospital ; Epidemiology ; Humans ; Patient Satisfaction ; Surveys and Questionnaires ; Seoul

PURPOSE: This study was conducted in order to evaluate the effect of a newly developed explanation handout in the emergency department (ED) between patient and guardian. METHODS: From August 24, 2013 to September 24, 2013, interviews were conducted to patient accompanying guardian, discharged from Seoul Medical Center ED. Four groups were divided according to non-handout or handout in addition to patient or guardian. Each group consisted of 50 candidates and allocated according to a random table. The explanation handout could be easily applicable automatically through the Electronic Medical Record. It contains the results of laboratory tests along with cautions by diagnosis. After discharge explanation, a survey was conducted in each group using questionnaires for evaluation of the effect on medical service satisfaction. RESULTS: A total of 97 candidates(49 patients, 48 guardians) in the non-handout group, and 99 candidates(50 patients, 49 guardians) in the handout group were enrolled. No statistical difference in epidemiology, except explanation time, was observed between the two groups. The handout group showed a higher score in all factors, however, explanation by physician (p<0.001), mean 3.61(+/-0.72) to 3.87(+/-0.73), understanding of medical status (p<0.001), mean 3.51(+/-0.75) to 4.11(+/-0.71), medical evaluation and treatment (p=0.001), mean 3.59(+/-0.72) to 3.92(+/-0.75), kindness of physician (p<0.001), mean 3.74(+/-0.81) to 4.09(+/-0.67), overall satisfaction (p<0.001), mean 3.60(+/-0.75) to 3.97(+/-0.75), willingness of revisit (p=0.023), mean 3.87(+/-0.73) to 4.09(+/-0.61), and willingness of recommendation (p<0.001), mean 3.66(+/-0.82) to 4.09(+/-0.66) showed statistically meaningful results. In a sub-analysis, statistically meaningful results were reanalyzed between patient and guardian. In the non-handout group, guardian showed higher scores in mean value in all factors, however, statistically meaningful results were observed for all factors, except understanding of medical status and medical evaluation and treatment. By application of the handout, 99 patients and 97 guardians showed higher scores in mean value in all factors. Patients showed statistically meaningful results in all factors but just in understanding of medical status in guardian. CONCLUSION: Results of this study showed that the explanation handout effectively increased medical service satisfaction. The effect of the explanation handout was more prominent in patients than guardians.
Diagnosis ; Electronic Health Records ; Emergencies* ; Emergency Medical Services ; Emergency Service, Hospital ; Epidemiology ; Humans ; Patient Satisfaction ; Surveys and Questionnaires ; Seoul

BACKGROUND: Atrioventricular reentry is the most common cause of supraventricular tachycardia in Korea. Radiofrequency catheter ablation(RFCA) is now accepted to be the safe and effective treatment modality for the elimination ofr accessory pathway conduction in patient with atrioventricualr reentrant tachycardia(AVRT). METHODS: To evaluate the clinical usefulness of RFCA for the treatment of AVRT, this study was conducted in 109 patients(male 68, female 41) with atrioventricular accessory pathway and documented AVRT after electrophysiologic study. RESULTS: A total of 112 accessory pathways were identified in 109 patients. The mean power outputs of the successful ablations at the atrial side of the annulus were higher than those at the ventricular side(34.0+/-8.9W versus 20.0+/-7.6W, p<0.01), but the maximum temperatures were lower at the atrial side of the annulus than those at the ventricular side (66.4+/-14.0degrees C versus 77.2+/-6.4degrees C, p<0.01). Accessory pathway conduction was eliminated in 102 of 112 pathways successfully(success rate 91v). There were 4 nonfatal complications(3.7%). 3 patients with hemopericardium and 1 with femoral artery thrombus, during or after ablation porcedures. Recurrences of AV reentrant tachycardia or delta wave on the electrocardiogram occured in 5 patients, and 4 of them had successful second procedures. There were no late complications during a mean follow-up period of 13+/-5 months. CONCLUSION: RFCA is highly effective and safe treatment modality in ablation accessory pathway conduction.
Catheter Ablation* ; Catheters ; Electrocardiography ; Female ; Femoral Artery ; Follow-Up Studies ; Humans ; Korea ; Pericardial Effusion ; Recurrence ; Tachycardia* ; Tachycardia, Supraventricular ; Thrombosis

BACKGROUNDThe zotarolimus-eluting stent has shown larger in-stent late lumen loss compared to sirolimus-eluting stents in previous studies. However, this has not been thoroughly evaluated in ST elevation myocardial infarction.

METHODSThis was a prospective, randomized, controlled trial evaluating angiographic outcomes in patients presenting with ST elevation myocardial infarction, treated with zotarolimus-eluting stents or sirolimus-eluting stents. From March 2007 to February 2009, 122 patients were randomized to zotarolimus-eluting stents or sirolimus-eluting stents in a 1:1 fashion. The primary endpoint was 9-month in-stent late lumen loss confirmed by coronary angiography, and secondary endpoints were percent diameter stenosis, binary restenosis rate, major adverse cardiac events (a composite of cardiac death, non-fatal myocardial infarction, and target vessel revascularization), and late-acquired incomplete stent apposition.

RESULTSAngiographic in-stent late lumen loss was significantly higher in the zotarolimus-eluting stent group compared to the sirolimus-eluting stent group ((0.49 ± 0.65) mm vs. (0.10 ± 0.46) mm, P = 0.001). Percent diameter stenosis at 9-month follow-up was also larger in the zotarolimus-eluting stent group ((30.0 ± 17.9)% vs. (17.6 ± 14.0)%, P < 0.001). In-segment analysis showed similar findings. There were no significant differences in binary restenosis rate, major adverse cardiac events, and late-acquired incomplete stent apposition.

CONCLUSIONSCompared to sirolimus-eluting stents, the zotarolimus-eluting stent is associated with significantly higher in-stent late lumen loss at 9-month angiographic follow-up in the treatment of ST elevation myocardial infarction. Although there was no significant difference in 1-year clinical outcomes, the clinical implication of increased late lumen loss should be further studied.

Aged ; Angioplasty, Balloon, Coronary ; adverse effects ; methods ; Drug-Eluting Stents ; adverse effects ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction ; therapy ; Sirolimus ; analogs & derivatives ; therapeutic use ; Treatment Outcome